Event time: 事件时间：
Published: 文章发布：
BBIO regulatory decision: BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with AchondroplasiaBridgeBio Pharma, Inc.（BBIO）披露重大监管决定
BBIO regulatory decision: BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia.
BridgeBio Pharma, Inc.（BBIO）披露重大监管决定。
For information only. Not investment advice.内容仅供参考，不构成投资建议。